. 2014 Nov 8;148(3):553–561. doi: 10.1007/s10549-014-3144-y

Table 2.

PFS in the ITT population and selected subgroups

	Median PFS, months^a		HR (95 % CI)^b	P value^c	P value (interaction)^d
	Eribulin	Control	HR (95 % CI)^b	P value^c	P value (interaction)^d
Overall population	4.0	3.4	0.90 (0.81, 0.997)	0.046
HER2 status
Positive	4.0	4.7	1.02 (0.78, 1.34)	0.865	0.185
Negative	3.7	3.0	0.84 (0.74, 0.95)	0.006	0.185
HER2 negative/hormone receptor positive	4.2	3.4	0.87 (0.75, 1.02)	0.084
ER status
Positive	4.2	3.7	0.86 (0.74, 0.99)	0.040	0.527
Negative	3.0	2.9	0.89 (0.75, 1.06)	0.212	0.527
Triple negative	2.8	2.6	0.78 (0.63, 0.96)	0.018	0.117
Non-triple negative	4.2	3.8	0.926 (0.82, 1.04)	0.21
Number of organs involved
≤2	4.2	4.2	0.92 (0.79, 1.07)	0.290	0.468
>2	3.7	2.8	0.86 (0.74, 0.99)	0.043	0.468
Visceral disease
Yes	3.8	3.3	0.94 (0.84, 1.05)	0.274
No	4.7	4.3	0.75 (0.56, 1.02)	0.065
Taxane refractory
Yes	3.5	2.8	0.90 (0.77, 1.05)	0.176
No	4.3	4.0	0.87 (0.75, 1.01)	0.079

ER estrogen receptor, CI confidence interval, HER2 human epidermal growth factor receptor 2, HR hazard ratio, ITT intent-to-treat, PFS progression-free survival, PR progesterone receptor

^aBased on curve adjusted by study

^bCox proportional hazards stratified by geographic region, prior capecitabine use and study (overall population additionally stratified by HER2 status; HER2-negative population additionally stratified by triple-negative status)

^cBased on stratified log-rank test

^dInteraction P values (Cox model) are given for subgroups for which significant differences were apparent